BioAffinity Net Receivables from 2010 to 2024

BIAFW Stock  USD 0.75  0.15  25.00%   
BioAffinity Technologies Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioAffinity Technologies Net Receivables regression line of quarterly data had mean square error of 59.5 B and geometric mean of  4,028. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
811.7 K
Current Value
852.3 K
Quarterly Volatility
292.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of bioAffinity Technologies Warrant over the last few years. It is BioAffinity Technologies' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

BioAffinity Net Receivables Regression Statistics

Arithmetic Mean112,852
Geometric Mean4,028
Coefficient Of Variation258.81
Mean Deviation191,764
Median1,530
Standard Deviation292,069
Sample Variance85.3B
Range850.7K
R-Value0.59
Mean Square Error59.5B
R-Squared0.35
Significance0.02
Slope38,788
Total Sum of Squares1.2T

BioAffinity Net Receivables History

2024852.3 K
2023811.7 K
202210.5 K

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables811.7 K852.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.